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PENILAIAN HASIL DAN KOS FARMAKOTERAPI EPILEPSI 
PEDIATRIK DI HOSPITAL PULAU PINANG 
 
ABSTRAK  
Epilepsi, lebih kerap terjadi dalam kalangan kanak-kanak berbanding dengan orang 
dewasa, dan ia boleh mempunyai kesan kognitif dan sosial yang memudaratkan. 
Dalam pediatrik, epilepsi biasanya mempunyai kerintangan terhadap drug kerana 
pembentukan dan  perkembangan sebenar epilepsi terbentuk di atas elemen-elemen 
dan urutan isyarat yang berbeza dengan perkembangan otak.  Justeru, epilepsi dalam 
kalangan kanak-kanak adalah suatu dilema kerana ia tidak boleh dirawat sebagai 
sebahagian daripada epilepsy dalam kalangan dewasa. Banyak sekali isu yang 
memberi kesan terhadap penyebab, pengurusan serta hasilan daripada epilepsi di 
Asia, termasuk faktor-faktor seperti psikososial, budaya, ekonomi, politik dan 
organisasi. Objektif am kajian ini adalah untuk menilai pengurusan pesakit pediatrik 
dengan epilepsi berstruktur-metabolisme, dari sudut klinikal dan ekonomi, di Klinik 
Pesakit Luar Neurologi Pediatrik,  Hospital Pulau Pinang, Malaysia. 
Bahagian pertama daripada kajian retrospektif membujur ini melibatkan pemerhatian 
klinikal. Pemerhatian susulan pada kanak-kanak yang terlibat dalam kajian ini 
dijalankan sehingga satu tahun selepas lawatan pertama.  Data yang diperlukan 
diambil daripada rekod perubatan. Dalam bahagian kedua pula, kajian ekonomi 
berasaskan prevalens tahunan dijalankan. Kos pengurusan epilepsi dianggar daripada 
perspektif penyedia (pihak hospital)  dengan menggunakan analisis mikrokos bawah-
atas, Data bil / carta perubatan (laporan kes) yang diperoleh daripada pihak hospital 
(penyedia) dikumpul untuk menganggar sumber yang digunakan. Di samping itu, 
analisis kos-keberkesanan dijalankan untuk menilai kegunaan pemantauan drug 
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terapeutik, dan drug antiepilepsi (AED) baru sebagai terapi tambahan dalam 
pengurusan pesakit pediatrik dengan epilepsi berstruktur-metabolisme.   
Dalam kalangan kanak-kanak dengan epilepsi berstruktur-metabolisme, bangsa 
Melayu, perempuan, berumur < 4 tahun, kanak-kanak dengan perkembangan yang 
lambat / ketidakupayaan intelek, dan  pesakit bermanifestasi dengan sawan setempat 
‗sawan seizure‘  adalah lebih bergerakbalas terhadap rawatan AED berbanding 
dengan pesakit sub-kumpulan lain. Tambahan pula, pesakit dengan rawatan 
politerapi biasanya  lebih sukar dan mempunyai kekerapan serangan yang tinggi 
berbanding dengan mereka yang menjalani rawatan monoterapi.  Kadar 
menggunakan AED dengan dos melebihi dos  yang disarankan adalah rendah (hanya 
10.83% daripada pesakit). Dari segi kawalan sawan yang lebih baik, penggunaan 
AED dengan dos melebihi dos yang disarankan tidak menunjukkan sebarang faedah 
berbanding dengan penggunaan agen tersebut pada dos yang disarankan.  Sekitar dua 
pertiga daripada pesakit mengalami kesan mudarat dalam tempoh susulan.  Kadar 
kesan mudarat hanya berhubung kait dengan umur pesakit.     
Pelaksanaan perkhidmatan pemantauan tahap AED serum merupakan suatu wadah 
berkuasa dalam mengurangkan kekerapan serangan. Walaupun banyak kesan 
mudarat berkaitan dengan kepekatan didokumenkan dalam fail pesakit oleh pegawai 
perubatan pelatih atau neurologis pediatrik,  namun ―Ketoksikan dijangka‖ tidak 
pernah dianggap sebagai satu alasan bagi permohonan pemantauan drug terapeutik 
dalam kajian semasa. ― Tahap periksa‘ dan ― Tahap periksa semula‖ adalah alasan 
bagi 52% dan 14% daripada permintaan asei, masing-masing. Secara 
keseluruhannya, terdapat persetujuan di antara saranan ahli farmasi klinikal dengan 
tindakan neurologis pediatrik terhadap pengurusan terapeutik. Sebahagian besar 
pemantauan tahap AED adalah sesuai. Dalam perkaitan dengan masa pensampelan, 
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lebih setengah daripada tahap AED serum diambil dengan betul.  Penggunaan AED 
baru sebagai terapi tambahan secara signifikannya tidak meningkatkan kawalan 
serangan dalam pesakit yang dikaji.   
Perkara yang paling mahal dalam senarai kos adalah AED, sementara pemeriksaan 
ultrabunyi adalah yang termurah.  Kemasukan ke hospital dan drug bukan 
antiepilepsi adalah item kedua dan ketiga termahal.  Kos TDM merupakan 
sebahagian kecil daripada keseluruhan perbelanjaan tahunan. Akhirnya, kos tahunan 
keseluruhan daripada pengurusan epilepsi adalah  RM 1690.13 bagi setiap pesakit 
setahun dan ia secara positifnya berkaitan dengan kekerapan serangan. 
Analisis peningkatan nisbah kos-keberkesanan bagi kedua-dua langkah pengukuran 
keberkesanan (iaitu perkadaran pesakit mencecah ≥50% pengurangan dalam 
kekerapan serangan, dan perkadaran pesakit yang 3 bulan bebas daripada serangan) 
mendapati pemantauan drug terapeutik adalah perkhidmatan yang paling kos-
berkesan. Dengan kata lain, penggunaan AED  generasi lama adalah dominan 
berbanding dengan penggunaan AED baru sebagai terapi tambahan. 
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PHARMACOTHERAPY OUTCOMES AND COST 
EVALUATION OF PAEDIATRIC EPILEPSY IN PENANG 
HOSPITAL 
 
 
ABSTRACT 
Epilepsy is more common in childhood than in adulthood, and it may have 
destructive cognitive and social effects. In paediatrics, epilepsy is usually drug 
resistant because the developmental progressions underlying epilepsy build on 
signalling elements and cascades that are distinctive to the development of the brain. 
Thus, epilepsy in children is a particular dilemma that cannot be treated as a subset 
of adult epilepsy. Numerous issues greatly affect the causation, management and 
outcome of epilepsy in Asia, including psychosocial, cultural, economic, political, 
and organisational factors. The general objective of this study was to evaluate the 
management of paediatric patients with structural-metabolic epilepsy. This included 
both clinical and economical standpoints in the Out-patient Paediatric Neurology 
Clinic at Hospital Pulau Pinang, Malaysia. 
In the first part of this retrospective longitudinal study, an observational clinical 
evaluation was conducted. The recruited children were followed up for one year after 
the first visit. The required data were extracted from the medical records. In the 
second part, an annual prevalence-based economic study was conducted. The total 
costs of epilepsy management were estimated from the provider (i.e., hospital) 
perspective, using a bottom-up, microcosting analysis. Medical chart/billing data 
(i.e., case reports) obtained from the hospital (i.e., provider) were collected to 
estimate the resources used. In addition, cost-effectiveness analysis was performed to 
assess the use of therapeutic drug monitoring, and new antiepileptic drugs as add-on 
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therapies in the management of paediatric patients with structural-metabolic 
epilepsy. 
Among children with structural-metabolic epilepsy, Malays ethnicity, females, 
patients less than 4 years of age, patients with GDD/ID, and patients manifested with 
focal seizure are more responsive to AED therapy than other subgroups of patients. 
Moreover, patients with polytherapy treatment are more complicated and have higher 
frequency of seizure attacks than those on monotherapy treatment. The rate of using 
antiepileptic drugs at doses above the recommended range was low (only 10.83% of 
the patients). In term of better seizure control, uses of antiepileptic drugs at doses 
above the recommended range shows no benefit over using these agents at the 
recommended doses. Around two-thirds of the patients experienced adverse events 
during the follow-up period. The rate of adverse effect was only associated with the 
patients‘ age.  
The implementation of the monitoring services of serum antiepileptic drug levels 
found to be as a powerful tool in reducing the patient‘s seizure frequency. Although 
many concentration-related adverse effects were documented in the patient‘s file by 
the house medical officer or paediatric neurologist, ―Suspected toxicity‖ was never 
rated as a reason for therapeutic drug monitoring request in the current study. ―Check 
level‖ and ―Recheck level‖ were the reasons in 52% and 14 % of the requested 
assays, respectively. By and large, there was a great agreement between the 
recommendations of clinical pharmacist and the actions of paediatric neurologist 
toward therapeutic management. An overwhelming proportion of the monitored 
antiepileptic drug levels were appropriately indicated. In relation to the time of 
sampling, more than half of the serum antiepileptic drug levels were appropriately 
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sampled. The use of new antiepileptic drugs as add on therapy did not significantly 
improve seizure control in the studied patients. 
The most expensive item in the costs list was antiepileptic drugs, whereas ultrasound 
examination represented the cheapest item. Hospitalization and non-antiepileptic 
drugs were the second and the third most costly items, respectively. The cost of 
TDM made-up only a small proportion of the total annual expenditure. Ultimately, 
the total annual cost of epilepsy management was RM 1690.13 per patient per year 
and it was positively correlated with seizure frequency. 
The analysis of incremental cost-effectiveness ratio for both of the effectiveness 
measures (i.e. the proportion of patients that achieved ≥50% reduction in seizure 
frequency, and the proportion of patients with 3-months seizure free) found 
therapeutic drug monitoring to be a cost-effective service. On the other hand, the use 
of old generation antiepileptic drugs was dominant over the use of new antiepileptic 
drugs as add on therapy. 
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 CHAPTER ONE: GENERAL INTRODUCTION 
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1.1 Background 
1.1.1 Epidemiology 
Epilepsy is a central nervous system (CNS) disorder that is characterized by a 
continued predisposition to seizures and by their cognitive, neurobiological, social, 
and psychological consequences (Fisher et al., 2005). The World Health 
Organisation (WHO) estimates that eight people per 1000 worldwide have epilepsy. 
Moreover, developing countries exhibit higher prevalence of epilepsy than developed 
countries (Commission on Tropical Diseases of the International League Against 
Epilepsy, 1994; Burneo et al., 2005; Preux and Druet-Cabanac, 2005). Even though 
Asia has experienced considerable economic expansion and development of health 
services, it is a diverse and resource-constrained continent. More than half of the 50 
million epileptic patients worldwide are living in Asia. Although a large number of 
studies have been conducted in Asia, information regarding the disease burden is 
limited (Mac et al., 2007). 
The prevalence of epilepsy ranges widely among Asian countries, from 1.5 to 14 per 
1000 (Li et al., 1985; Aziz et al., 1994; Aziz et al., 1997; Lee et al., 1997; Loh et al., 
1997; Su et al., 1997; Mani et al., 1998; Radhakrishnan et al., 2000; 
Asawavichienjinda et al., 2002; Huang et al., 2002; Ray et al., 2002; Wang et al., 
2002; Bharucha, 2003; Fong et al., 2003; Mori, 2003; Rajbhandari, 2003; Wang et 
al., 2003; Murthy et al., 2004; Cuong et al., 2005; Chen et al., 2006; Rajshekhar et 
al., 2006; Tran et al., 2006). This broad variation may be partially a consequence of 
the implementation of different questionnaire styles and/or different study methods 
(Cuong et al., 2005; Tran et al., 2006). The median prevalence for Asian countries is 
estimated to be 6 per 1000, which is much lower compared with other developing 
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countries in different areas of the world (15 per 1000 in sub-Saharan Africa and 18 
per 1000 in Latin America (Burneo et al., 2005; Preux and Druet-Cabanac, 2005)). 
Information on the incidence of epilepsy in Asia is limited. Only five estimates are 
available, mainly for China and India (Li et al., 1985; Mani et al., 1998; Sawhney et 
al., 1999; Ray et al., 2002; Wang et al., 2002). In China, the reported incidence rates 
were low, from 28.8 per 100,000 person-years (Wang et al., 2002) to 35 per 100,000 
person-years in the general population (Li et al., 1985). India has a higher incidence 
of 60 per 100,000 person-years (Sawhney et al., 1999). On the whole, these rates are 
not different from the reported results in developed countries, where the incidence of 
epilepsy is 24-53 per 100,000 person-years (Jallon, 2002). 
Demographic characteristics may be driving factors for the incidence and prevalence 
of the disease. Two peaks ages have been found. Childhood is one of the peak ages 
for disease incidence (Aziz et al., 1997; Tran et al., 2006), and young adulthood is 
the other peak age for prevalence (Li et al., 1985; Radhakrishnan et al., 1999; 
Sridharan and Murthy, 1999; Radhakrishnan et al., 2000; Ng et al., 2001; Fong et al., 
2003; Mannan, 2004; Tran et al., 2006). A Chinese study that was conducted in 
Shanghai illustrated two prevalence age peaks: one between 10 to 30 years old and 
one in people over 60 years old (Huang et al., 2002). Both the incidence and 
prevalence of epilepsy in developed countries reflect a bimodal distribution, with a 
primary peak in childhood and the other peak in old age (Sander et al., 1990; Jallon, 
2002; Lim, 2004). The most plausible explanation for the absent peak in the elderly 
in Asian regions is the younger population compared with that of developed 
countries (Mac et al., 2007). Generally, Asian male and female prevalence rates of 
epilepsy are not dramatically different. However, the disease tends to be more 
common in males than in females (Aziz et al., 1997; Lee et al., 1997; Mani et al., 
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1998; Sridharan and Murthy, 1999; Ng et al., 2001; Huang et al., 2002; Fong et al., 
2003; Rajbhandari, 2003; Tran et al., 2006). 
Two Asian studies (in Pakistan and India) found a higher prevalence of epilepsy in 
rural areas than in urban areas (Aziz et al., 1997; Rajshekhar et al., 2006). 
Consistently, an Indian meta-analysis study showed the same trend in the prevalence 
of epilepsy. The prevalence in the rural areas was 5.5 per 1000 compared with 5.1 
per 1000 in urban areas (Sridharan and Murthy, 1999). Several clinical studies have 
been conducted in Asia (some in Malaysia), but few have described the distribution 
of seizure types in community-based settings. Moreover, the assessment of outcomes 
from various studies is not easy because the disease classifications are not 
harmonised (Win, 1993; Loh et al., 1997; Manonmani and Tan, 1999a; 
Radhakrishnan et al., 2000; Ling Kwong et al., 2001; Ng et al., 2001; Wong, 2001; 
Fong et al., 2003; Thomas et al., 2005; Tran et al., 2006). 
The prevalence rates of idiopathic, cryptogenic and symptomatic epilepsy in Asia 
were 4-42%, 13-60%, and 22-53% respectively (Manonmani and Tan, 1999a; Ling 
Kwong et al., 2001; Ng et al., 2001; Wong, 2001; Fong et al., 2003; Tran et al., 
2006). The ranges of partial and generalised seizures in Asian epileptic patients were 
31-50% and 50-69%, respectively (Loh et al., 1997; Radhakrishnan et al., 2000; Ling 
Kwong et al., 2001; Tran et al., 2006). The dominance of generalised epilepsy and 
the broader range of cryptogenic syndrome can be attributed to the dissimilarities in 
the level of imaging researches and to the clear shortage of standardised 
classification and terminology in Asian studies. Electroencephalographic information 
is frequently not obtainable, which could also have affected the prevalence of the 
idiopathic epilepsy described in a number of studies. The accurateness of the clinical 
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classification of epilepsy in Asia necessitates population-based studies with 
electroencephalographic recording (Mac et al., 2007). 
1.1.2 Aetiology 
The causes of epilepsy in the Asian population appear to be head injury, birth 
trauma, and intracranial infections. Few publications describe the aetiology of 
epilepsy, and these are mostly case-control or cohort studies. Usually, head trauma 
and stroke are the primary causes of epilepsy in areas of higher socioeconomic 
development (Li et al., 1985; Rajbhandari, 2003; Hui and Kwan, 2004; Shichuo et 
al., 2004).  
Posttraumatic epilepsy is considered to be one of the most important complications 
of head injury in Asia. In fact, it may account for 5% of total epilepsy, and 20% of 
symptomatic epilepsy results from head injuries (Shichuo et al., 2004). In other parts 
of the world, in developing countries such as those in Latin America or sub-Saharan 
Africa, the high level prevalence of epilepsy may be due to CNS infections. A 
number of diseases have been listed by The Commission on Tropical Diseases of The 
International League Against Epilepsy as being causes of epilepsy, including 
malaria, tuberculosis, schistosomiasis, acquired immunodeficiency syndrome, and 
cysticercosis, but the commonest cause of epilepsy appears to be cysticercosis 
(Commission on Tropical Diseases of the International League Against Epilepsy, 
1994). 
Several studies in Latin America (Brutto et al., 2005; Garcia and Del Brutto, 2005) 
and Africa (Preux and Druet-Cabanac, 2005) showed a correlation between 
neurocysticercosis and epilepsy. Some studies reported that the cause of half of the 
epilepsy cases was neurocysticercosis (Kamgno et al., 2003; Rajshekhar et al., 
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2003), and seizures occurred in the majority of patients with parenchymal 
cysticercosis (Rajshekhar et al., 2003). Although several studies described the 
existence of cysticercosis in Asia (Veliath et al., 1985; Theis et al., 1994; Chung and 
Chi, 1998; Kuruvilla et al., 2001; Erhart et al., 2002; Ito et al., 2003; Rajshekhar et 
al., 2003; Willingham et al., 2003; Dorny et al., 2004; Joshi et al., 2004; Rajshekhar, 
2004; Yindan et al., 2004), only a small number of studies have been conducted to 
examine the association between neurocysticercosis and epilepsy. Neurocysticercosis 
is almost certainly an imperative cause of seizures and epilepsy in areas with a high 
prevalence of taenia solium infection. The high prevalence is present in several Asian 
countries: India, Vietnam, China, Bali, Papua, and Sulawesi in Indonesia. 
Cysticercosis is almost never identified in highly developed Asian countries such as 
South Korea (Chung and Chi, 1998). 
Paragonimiasis is common in several Asian countries: Vietnam, the Philippines, 
China, Japan, and South Korea (Tran et al., 2004; Strobel et al., 2005). Through 
migration, the lung fluke may reach the brain and cause various neurological 
syndromes including seizures and epilepsy (Higashi et al., 1971; Kaw and Sitoh, 
2001; Choo et al., 2003). Nevertheless, no research has measured the significance of 
paragonimus infection in epilepsy. 
In Asia, malaria an endemic infectious disease, with over 3 million cases per year. 
Cambodia, Pakistan, Burma, India, Indonesia, Papua New Guinea, and Bangladesh 
each have more than 50,000 cases per year (Malaria, 2005). In Thailand, a 
retrospective survey of patients with childhood malaria (irrespective of the existence 
of cerebral malaria) found that 7.7% of the patients had convulsions (Wattanagoon et 
al., 1994). In another study, 60% of 104 cases with cerebral malaria had developed 
convulsions (Faiz et al., 1998). Nevertheless, no systematic studies have described 
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the relationship between malaria and epilepsy in Asia. However, this link was 
recently supported by a case-control study in Gabon and a cohort study in Mali in 
Africa (Ngoungou et al., 2006a; Ngoungou et al., 2006b). 
Japanese encephalitis is another endemic disorder that has several consequences, 
including seizures and epilepsy. A large part of China, the Indian subcontinent, and 
Southeast Asia are affected (Solomon et al., 2000). Two-thirds of Japanese 
encephalitis patients experience acute symptomatic seizures, and 13% of them 
develop chronic epilepsy (Murthy, 2003). 
1.1.3 Genetic aspects 
In India, two studies have illustrated that there is no association between being a twin 
and having epilepsy. The twins of an individual with epilepsy was not at a 
significantly increased risk of epilepsy (Jain et al., 1999; Sharma, 2005). Although 
some Chinese studies showed no significant association between susceptibility genes 
and epilepsy  (Chen et al., 2003a; Chen et al., 2003b; Lu et al., 2003; Ren et al., 
2005), some other studies have suggested that familial history of epilepsy and 
parental consanguinity may be risk factors. In two different Indian studies, familial 
history of epilepsy was two to three times higher among epileptic patients than 
among controls (Sawhney et al., 1999; Nair and Thomas, 2004). This results was 
consistent with the findings of two other epileptic studies in China and Laos (Zeng et 
al., 2003; Tran et al., 2006). This degree of risk was similar to that of studies from 
Africa (Preux and Druet-Cabanac, 2005). 
Consanguineous marriage is popular in certain Asian societies, particularly among 
Muslim and Indian people. Parental consanguinity is more common among patients 
than among controls (Nair and Thomas, 2004). Another study on epileptic patients of 
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Indian origin in Malaysia demonstrated that about one-third had a parental 
consanguineous marriage and that there was a significant association between 
parental consanguinity and two types of epilepsy (idiopathic and cryptogenic 
epilepsy) (Ramasundrum and Tan, 2004). Consanguinity could therefore be targeted 
for prevention of epilepsy. 
1.1.4 Epilepsy management 
There is wide variability in the management of epilepsy in different regions. In Asia, 
this variability might be attributed to many factors such as economic situation, 
quality of health care, and secondary services, rural or urban habitation, and the 
cultural frameworks of societies (Tan and Lim, 1997; Scott et al., 2001). Based on 
the WHO Atlas Epilepsy Care (World Health Organization. International Bureau for 
Epilepsy. International League Against Epilepsy, 2005), the median number of 
hospital beds devoted to epilepsy management per 100,000 population is extremely 
small in Asia: 0.05 in Southeast Asia and 0.46 in the western Pacific; these figures 
are lower than those in Africa (0.55) and far lower than those in Europe (1.65).  
Likewise, the majority of Asian countries have a very low number of neurologists. In 
2004, WHO found that there was less than one neurologist per million residents in 
India, Laos, and Bangladesh. However, Japan had a range of one to 50 neurologists 
per million people (World Health Organization, 2004; World Health Organization. 
International Bureau for Epilepsy. International League Against Epilepsy, 2005). 
In Asia, technologies that are used in the diagnosis of epilepsy, such as 
electroencephalography (EEG), computed tomography (CT), and magnetic resonance 
imaging (MRI), are generally available. However, different geographical areas may 
exhibit various degrees of accessibility. In countries like Japan, South Korea, 
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Singapore, and Taiwan, which are considered to be more developed economic 
regions, high qua medical services are highly accessible and obtainable for most of 
the population. By contrast, in other countries such as Cambodia, East Timor, Laos, 
or Mongolia, facilities for EEG, MRI, or CT are mostly unavailable (Tan and Lim, 
1997). 
Antiepileptic drugs (AEDs) are the easiest and most harmless way to manage 
epilepsy. In Asia, a range of old-generation AEDs (phenobarbital, carbamazepine, 
valproic acid, phenytoin, clonazepam, ethosuximide, and primidone) is commonly 
used. The exact agent used depends on the therapeutic society and observation in 
each country (International League Against Epilepsy, 1985; Chen et al., 2000b; 
Thomas et al., 2001; Seneviratne et al., 2002; Liu et al., 2003; Rajbhandari, 2003; 
Silpakit and Silpakit, 2003; Gunawan, 2004; Hui and Kwan, 2004; Kariyawasam et 
al., 2004; Krishnan et al., 2004; Lim, 2004). New generation AEDs, such as 
topiramate, lamotrigine, vigabatrin, gabapentin, tiagabine, or felbamate, are 
commonly used in Singapore, Malaysia, China, and in a few of the less urbanised 
countries such as the Philippines and Vietnam (Nassiri and Stelmasiak, 2000; 
Epilepsy, 2004). 
There is a wide range of drugs accessibility across Asia depending on the cultural 
framework (level of development, urbanisation, etc). Nonetheless, accessibility is 
most likely to be easier in Asia than in Africa (Mac et al., 2007). Subsidisation of 
AEDs appears to be quite limited or not available for most parts of Asia. Even for the 
most popular old-generation AEDs, families or patients pay out of pocket and in 
some instances beyond their means. For example, the annual expenses of one of the 
cheapest antiepileptic agents (i.e. phenobarbital) are approximately US $30 in Laos, 
which is equivalent to the monthly income of a school-teacher. Consequently, not all 
10 
 
patients can have long-term therapeutic management if it is not supported or 
subsidised (Mac et al., 2007). In one Indian study, the average yearly expenditure 
(direct and indirect) of out-patient management of epilepsy is US $47 per patient. 
Moreover, the yearly cost for all patients undergoing emergency and inpatient 
management at a secondary hospital is estimated to be US $810.50 and US $168.30, 
respectively. Overall, the loss of productivity was much higher than the cost of 
treatment, and it would be worthy for governments or societies to monopolize in 
epilepsy management (Krishnan et al., 2004). 
1.1.5 Treatment gap 
The International League Against Epilepsy (ILAE) held a workshop and gave a clear 
definition for the term ―seizure treatment gap‖, which was ―the difference between 
the number of people with active epilepsy and the number whose seizures are being 
appropriately treated in a given population at a given point of time, expressed as a 
percentage‖.  Active epilepsy is defined as ―two or more unprovoked epileptic 
seizures on different days in the prior year that are disabling to the individual‖ 
(Meinardi et al., 2001; Scott et al., 2001). Ninety percent of patients with epilepsy in 
sub-Saharan Africa and Latin America receive insufficient treatment or no treatment 
by any means (Shorvon and Farmer, 1988; Anonymous, 1997b; Scott et al., 2001). 
On the other hand, the treatment gap in Asia was 29-98%, with the ranging value of 
50 to 80% in most countries. The rural areas illustrated a higher seizure treatment 
gap than urban areas. The shortage of AEDs and the lack of epileptic knowledge 
influence the treatment gap in rural areas (Bharucha et al., 1988; Koul et al., 1988; 
Aziz et al., 1994; Aziz et al., 1997; Mani, 1997; Pal, 1999; Sridharan and Murthy, 
1999; Radhakrishnan et al., 2000; Ray et al., 2002; Wang et al., 2002; Gourie Devi 
et al., 2003; Wang et al., 2003; Rajbhandari, 2004; Bharucha NE et al., July 1997). 
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In conclusion, there is a range of biological diversity in epilepsy across Asia and the 
western countries; in particular, epilepsy affects those of a young average age and 
lesser physique among Asian countries. Climatic distinctions, such as those reflected 
in the elevated prevalence of Japanese encephalitis and malaria, remain sources of 
acute symptomatic seizures in several regions of Asia. Numerous issues greatly 
affect the causation, management and outcome of epilepsy in Asia, including 
psychosocial, cultural, economic, political, and organisational factors. As a 
consequence, the precedence should be set for these issues in research to pick up 
epilepsy care in Asia (Chong-Tin, 2007; Mac et al., 2007). 
1.1.6 Underlying type of cause 
the ILAE replaced the old terms idiopathic, symptomatic, and cryptogenic with 
modified conceptual terms genetic, structural–metabolic, and unknown (Berg et al., 
2010). Genetic epilepsy is directly resulted of an identified genetic defect(s), in 
which seizures are the core symptom of the disorder. In structural-metabolic epilepsy 
there is an apparent structural or metabolic disease. Structural lesions may results 
from trauma, stroke, and infection or it might be of genetic origin (e.g., tuberous 
sclerosis). In ―unknown‖ cases, so far, the nature of the underlying cause is 
unidentified. 
1.2 Problem statement 
A logical strategy for childhood epilepsy care obliges the scientific realisation that 
the various types of seizures may occur at diverse age strata and have a variety of 
primary causes. It is difficult to define a specific type of AEDs for these patients. For 
decades, epilepsy therapeutic management has been restricted to the use of several 
agents that are considered the old generation AEDs: phenytoin, phenobarbital, 
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carbamazepine, sodium valproate, primidone, and ethosuximide. Whilst the clinical 
application and therapeutic implementation of these different AEDs are well 
recognised in adult patients, these drugs are not often applicable to the seizure and 
epilepsy care in children. In addition to the accurate selection of the AED, physicians 
also must keep in mind the potential effects of the chosen AED on the biological and 
psychosocial development of the child patient (Rahman et al., 2005).  
The most desirable outcome in the utilisation of AEDs is for patients to be free of 
seizures for the rest of their lives, but many different aspects govern the outcomes of 
AEDs treatment in the paediatric population: the recognition of underlying causes, 
the type of seizures, selection, dosing and monitoring of AEDs, and the 
pharmacokinetic parameters of AEDs. Each of these is necessary for successful 
management; however, there is a scarcity of duly-performed outcome-based studies 
in childhood epileptic patients.  
The present AED expansion structure fundamentally renders children with epilepsy 
―therapeutic orphans‖. This is obviously seen in children with severe persistent 
epilepsy syndrome, a disease that does not occur in adults. Consequently, such 
children can only hope that through chance their diseases will gain from the 
therapeutic improvement projected in adult patients with partial epilepsy (Trevathan, 
2003). Accordingly, the clinical application and therapeutic use of AEDs are better 
documented and standardised in adults than in children (Hasan et al., 2010).  
This revolutionisation in the treatment and the new focus on cost restraint and care 
management are raising the attention towards the economic features of epilepsy. Cost 
estimates are increasingly needed by government payers, insurance companies, and 
others groups that are attentive to the allotment of limited research and treatment 
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dollars. These cost estimates are required to show the cost of having epilepsy and to 
detail the assortment of features that assign the distribution of the burden across the 
population. Cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) are 
considered necessary for the assessment of health services and new treatments 
(Begley et al., 1999b). 
1.3  Rationale of the study 
Whilst the types and number of AEDs are expanding, the management of epilepsy 
(mostly childhood epilepsy) remains a challenge. Seizure episodes affect 25% or 
more of the paediatric population with childhood epilepsy (White, 1997). Amongst 
children up to 16 years of age, approximately 4 to 10% experience at least one 
seizure. In epidemiology terms, research suggests that approximately 150,000 
children will suffer a first-time unprovoked seizure each year, and of those, 30,000 
will manifest epilepsy (McAbee and Wark, 2000). 
The aim of using AEDs in treating epilepsy is to eliminate seizures without side 
effects (Perucca, 1996b; Guberman A and Bruni J, 1999). A considerable number of 
patients with epilepsy are still unable to attain this aim, even with the introduction of 
the new generation of AEDs (Brodie and Dichter, 1996; Mattson et al., 1996). There 
are various rationales for this quandary, including, the wrong identification of seizure 
type and subsequent inaccurate AED selection, inter-patient variations in dose-
response and AED tolerability, inconsistent degrees of adherence with prescribed 
treatment, flawed approaches in regulating medication (Duncan JS, 1996; Devinsky, 
1999), and incorrect utilisation of therapeutic drug monitoring (TDM) service (e.g., 
misinterpretation) (Dodson, 1989; Commission on Antiepileptic Drugs. International 
League Against Epilepsy, 1993). 
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The present need for cost realisation in the context of health has called for the 
financial appraisal of health care services and facilities as well as pharmaceuticals to 
recognise those drugs which are worth the most money in caring for patients. Hence, 
for situations in which a number of competing drugs or amenities are present, 
economic analyses compare the expenditure and outcomes of treatment with services 
or drugs are being the criterion. In epilepsy, the establishment of TDM services and 
the introduction of new AEDs have also motivated economic analyses to balance the 
costs to outcomes. Wherever better effectiveness cannot be revealed, economic 
evaluations must quantify the resource implications of differing adverse-event 
profiles to evaluate the rationalisation for higher prices (Shakespeare and Simeon, 
1998). 
1.4 Significance of the study 
Epilepsy is more common in childhood than in adulthood, and it may have 
destructive cognitive and social effects. In paediatrics, epilepsy is usually drug 
resistant because the developmental progressions underlying epilepsy build on 
signalling elements and cascades that are distinctive to the development of the brain 
(Ben-Ari and Holmes, 2006). Thus, epilepsy in children is a particular dilemma that 
cannot be treated as a subset of adult epilepsy. 
The clinical findings of this study will provide the fundamental basis for health 
professionals to understand the logical and the appropriate utilisation of health 
services (e.g., TDM) in the management of childhood epilepsy in Malaysia. 
Moreover, these results will clarify the picture for the implementation of a new 
generation of AEDs as adjuvant. Consequently, the study outcomes will lead to 
better patient care, optimise seizure control, enhance patient quality of life, avoid 
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possible adverse effects and preserve the patient aptitude in conducting daily 
activities. 
In health economics, the research is a financial appraisal, and it gives the facts of the 
prospective outlays and interests of health care interferences. In epilepsy, such 
investigations are still in their infancy, and there is an urgent call for such studies in 
such areas, for example, the awareness that incorrect use of a service (e.g., TDM) 
may result in intolerable waste of funds (Bussey and Hoffman, 1983; Chadwick, 
1987; Hallworth, 1988) and even harm to patient health (Beardsley et al., 1983a; 
Woo et al., 1988; Jackson et al., 1994). Likewise, expensive new AEDs are gaining 
popularity, and economic assessment is essential, which should counts on measures 
of social rehabilitation as well as seizure frequency, which is presently the standard 
outcome measure (Cockerell et al., 1994). Hence, the results of this study will 
highlight the significance of optimising seizure control as a way to reduce the costs 
of epilepsy, not only for the hospital, but also for society. 
1.5 Study objectives 
The objective of this study was to evaluate the management of paediatric patients 
with structural-metabolic epilepsy. This included both clinical and economical 
standpoints in the Out-Patient Paediatric Neurology Clinic at Hospital Pulau Pinang, 
Malaysia. 
1.6 Thesis overview 
Chapter 2 describes the clinical evaluation method and its findings for assessing the 
actual medical practice in the management of epilepsy at the Out-Patient Paediatric 
Neurology Clinic in Hospital Pulau Pinang, Malaysia. The chapter details the impact 
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of implementing TDM services on clinical seizure outcomes. Additionally, this 
chapter describes the paediatricians‘ adherence to the TDM recommendations. In 
relation to the above, the assessment of the appropriateness of the determination of 
serum levels of AEDs is explained as well. Furthermore, the drug utilisation patterns 
of AEDs prescribed for the management of different types of epilepsy and the 
evaluation of clinical outcomes for both generations (old and new) of AEDs in 
paediatric population are examined. 
In Chapter 3, a comprehensive demonstration is written regarding the designation 
and implementation of a cost methodology through the process of patient care to 
calculate the unit costs of each service or activity that was utilised by the studied 
patients, starting from the paediatric neurology clinic to the rest of the other 
departments in the hospital, including the pathology department, radiology 
department, neurology clinic, and pharmacy department.  
Chapter 4 illustrates a number of CEA on the basis of information on the proportion 
of patients that achieved ≥50% reduction in seizure frequency, and the proportion of 
patients with 3 months seizure free. The chapter comprises two major sections. The 
first section includes the CEA of utilising TDM services. The second section 
demonstrates valuable comparisons of the use of new generation AEDs as adjuvant 
therapies versus old generation alone. 
Chapter 5, the last chapter, contains concludes with a general summary of the study 
findings and limitations together with a set of recommendations for further work. 
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 CHAPTER TWO: CLINICAL EVALUATION 
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2.1 Introduction 
2.1.1 Therapeutic drug monitoring 
2.1.1.1 Background and historical introduction 
Until the 1960s, trial and error was the most common scenario for drug management  
(Barr, 1985; Robinson and Taylor, 1986). Even though the guiding principles were 
usually obtainable and believable to be efficient and safe, majority of practitioners 
implement dosing in an empirical approach. Doses were frequently started at low 
ranges and increased gradually until an improvement is achieved or, in spite of the 
guidelines, toxic effects manifested. Characteristically, over 50% of the adverse drug 
reactions in main teaching hospitals in the 1960s were precipitated by doses that 
were too high for the patients (Koch-Weser et al., 1969). Recognising that several 
early studies in the 1950s (Sokolow and Edgar, 1950; Talbott, 1950; Geraci et al., 
1956; Buchthal et al., 1960) had proposed that a serum concentration of a drug could 
be utilised to identify pharmacokinetic variations among different patients as well as 
to steer responses to therapy; for those reasons, researchers were concerned to 
develop this work to enhance drug effectiveness and safety. 
With the realisation that standard dosage regimens resulted in unreliable patient 
outcomes, health professionals required a more systematic training about the 
application of scientific technology to shape drug treatment designed for the 
individual patients. These requirements encourage researchers to find analytical 
facilities that can more precisely describe the pharmacokinetic characteristics and 
therapeutic serum concentration ranges of the drugs. Hence, at the end of the 1960s, 
some initial studies were published on identifying pharmacokinetic parameters and 
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therapeutic serum concentration ranges for a number of drugs including antibiotics, 
antiepileptics, cardiac drugs, and bronchodilators (Smith et al., 1969; Harrison et al., 
1970; Beller et al., 1971; Koch-Weser and Klein, 1971; Jelliffe et al., 1972; Jenne et 
al., 1972; Lund, 1972; Ogilvie and Ruedy, 1972; Mitenko and Ogilvie, 1973; Koch-
Weser et al., 1974; Noone et al., 1974). 
Thus, the last three decades showed an obvious growth in the concept of TDM, 
especially in the area of pharmacokinetics and pharmacodynamics research. This 
development was related to the combination of interrelating and jointly strengthening 
pharmacokinetics and pharmacodynamics issues (Barr, 1985). Optimising drug 
therapy was the main goal of applying clinical pharmacokinetics and 
pharmacodynamics principles. The optimisation included minimising the probability 
of drug toxicity and maximising the benefits of achieving the desired therapeutic 
effect, particularly in the instances where the blood concentration of the drug could 
be a better predictor of the desired effect(s). Therefore, increased efficacy without 
unacceptable toxicity or reduced toxicity without compromising efficacy may justify 
the use of the principles of pharmacokinetics and pharmacodynamics to improve the 
clinical outcome and drug therapy. However, TDM has minimal benefit for drugs 
with a wide therapeutic index (i.e., drugs that do not exhibit toxicity at serum 
concentrations or doses required for therapeutic effect) (Michael E. Burton et al., 
2006). 
In the 1970s and early 1980s, the extensive exploration and application of TDM 
occurred secondary to the increase in the interest and enthusiasm in the therapeutic 
serum drug range. In addition, physicians had a strong interest in monitoring more of 
their patients; in effect, pharmacists were given a great chance to have a real 
contribution in drug treatment. Pharmacists by training, have a better understanding 
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of drug serum concentrations, dosage adjustment calculations, and general drug 
monitoring. In addition pharmacists also have the eagerness and accessibility for 
TDM contribution, supported by the growing acceptance of the expanded 
responsibilities for pharmacists by other health care providers. Moreover, 
manufacturers of laboratory equipment were also competing to produce a faster and 
more precise analytic technology, ensuring nearly a 500-fold expansion in the TDM 
products in the last 25 years. By contrast, some researchers were queried to the 
development of TDM and to the question of whether its value had been exaggerated 
(Sjoqvist, 1985; Spector et al., 1988; McInnes, 1989). 
2.1.1.2 Rationale for monitoring serum concentrations of AEDs 
Dose individualisation is considered to be an important element in the management 
of epilepsy. However, the recognition of the optimal dose solely based on clinical 
judgment can be complicated or tricky. There are three justifications for this. First, in 
view of the fact that AED therapy is prophylactic and seizures may arise at irregular 
periods of time, it is not usually easy to promptly determine whether the arranged 
dose will be satisfactory to generate long-term seizure control. Second, it is difficult 
to discriminate the clinical signs and symptoms of toxicity from the manifestation of 
causal disorders. Third, there are no obvious laboratory indicators for clinical 
efficiency for the most general manifestations of AED toxicity, for example, CNS 
adverse drug effects (Patsalos et al., 2008). 
The value of TDM service often shows a degree of discrepancies among different 
AEDs, and the value relies on their pharmacological characteristics. However, the 
epilepsy-interrelated grounds and certainly the indications for TDM are analogous 
for all AEDs. TDM is expected to be of particular importance for AEDs that display 
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obvious intra- or interindividual variability in pharmacokinetics. Regardless of the 
disparity in pharmacological properties of different monitored drugs, TDM is also 
likely to be useful in determining drug compliance, in pointing out toxicities to drug 
therapy, and in managing overdoses and drug interactions (Eadie, 1998; Patsalos et 
al., 2008).  
2.1.1.3 Monitoring free drug concentrations 
Serum or plasma is deemed to be the best mediums for TDM in which the 
concentration may be monitored. Both biospecimen can be used interchangeably; 
however, in terms of consistency, it is better to use one or the other (Patsalos et al., 
2008). Saliva is a matrix of restrictedly rising usefulness for some AEDs. In the 
majority of clinical situations, the monitoring of total serum concentrations are 
sufficient; undeniably, the most regular technique for measuring AEDs in sera do not 
differentiate between the elements of the monitored drug that is free (unbound) and 
that is bound to serum or plasma proteins (Eadie, 1998; Patsalos et al., 2008). 
Nevertheless, because only the free drug exists to shift across the blood-brain barrier 
where the pharmacological effect will occur, in specific clinical situations whereby 
the extent of protein binding is changing, patient therapy with AEDs would be most 
appropriately tailored based on free serum concentrations (Eadie, 1998; Patsalos et 
al., 2008; Salih et al., 2010). 
Different clinical settings may exhibit alterations in the plasma protein binding of 
AEDs, including hypoalbuminemia (patients with burns, old age, pregnancy, 
acquired immunodeficiency syndrome, etc.) (Levine and Chang, 1990; Fedler and 
Stewart, 1999); patients with uremia (Peterson et al., 1991); drug-drug interactions; 
displacement of the drug from its plasma protein binding by another drug (Kilpatrick 
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et al., 1984; Burt et al., 2000); and patients with chronic liver disease (Dasgupta, 
2007). 
In some situations, monitoring of total serum concentrations may be unreliable. This 
is typically observed when the free fraction of the AEDs increases. As a 
consequence, the therapeutic and toxic effects will be seen at total drug 
concentrations that are lower than usual (Perucca et al., 1981; Barre et al., 1988; 
Salih et al., 2010).  
On the whole, drugs that highly bind to plasma proteins (Table 2.1) are the most vital 
candidates for monitoring free drug concentrations because the variation in protein 
binding creates a clinically noteworthy effect in changing the free drug 
concentrations. However, free drug concentrations of old generation AEDs, such as 
phenytoin, valproic acid, and carbamazepine are still the most requested by clinicians 
(Perucca, 1984; Dasgupta, 2007; Patsalos et al., 2008; Salih et al., 2010). 
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Table 2.1: Pharmacokinetic parameters of the most commonly used antiepileptic drugs (Patsalos et al., 2008) 
Drug 
 
Oral 
bioavailability 
(%) 
Serum 
protein 
binding 
(%) 
Time to peak 
concentration 
(h) 
Time to 
steady-state
l
 
(days) 
Half-life in the 
absence of 
interacting 
comedication 
(h) 
Half-life in 
patients 
comedicated 
with enzyme 
inducers (h) 
Comment Reference 
range (mg/L) 
Carbamazepine 
 
≤85 
 
75 2–9a 
 
2–4b 
 
8–20b 
 
5–12b 
 
Active 10,11 
epoxide 
metabolite 
contributes 
to clinical effects 
 
4–12 
 
Clobazam 
 
≥95 
 
85 1–3 
 
7–10c 
 
10–30 
 
? 
 
Active N-
desmethyl-
metabolite 
contributes 
to clinical effects 
0.03–0.3 
(clobazam) 
 
0.3–3 
(desmethyl 
metabolite) 
 
Clonazepam 
 
≥95 
 
85 1–4 
 
3–10 
 
17–56 
 
11–35 
 
7-amino 
metabolite 
retains some 
pharmacological 
activity 
0.02–0.07 
 
Ethosuximide 
 
≥90 
 
0 1–4 
 
7–10 
 
40–60 
 
20–40 
 
 40–100 
 
Felbamate 
 
>90 
 
25 2–6 
 
3–4 
 
16–22 
 
10–18 
 
 30–60 
 
Gabapentin 
 
<60
d
 
 
0 2–3 
 
1–2 
 
5–9 
 
5–9 
 
 2–20 
 
Lamotrigine 
 
≥95 
 
55 1–3a 
 
3–6 (5–15 
with 
valproic acid 
comedication) 
15–35 (30–90 
with valproic 
acid 
comedication) 
8–20 (15–35 
with valproic 
acid 
comedication) 
 2.5–15 
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Table 2.1: Continued  
Drug 
 
Oral 
bioavailability 
(%) 
Serum 
protein 
binding 
(%) 
Time to peak 
concentration 
(h) 
Time to 
steady-state
l
 
(days) 
Half-life in the 
absence of 
interacting 
comedication 
(h) 
Half-life in 
patients 
comedicated 
with enzyme 
inducers (h) 
Comment Reference 
range (mg/L) 
Levetiracetam 
 
≥95 
 
0 1 
 
1–2 
 
6–8 
 
5–7 
 
 12–46 
 
Oxcarbazepine 
 
90
e
 
 
40
e
 3–6e 
 
2–3e 
 
8–15e 
 
7–12e 
 
 3–35e 
 
Phenobarbital 
 
≥95 
 
55 0.5–4 
 
12–24 
 
70–140 
 
70–140 
 
 10–40 
 
Phenytoin 
 
≥80f 
 
90 1–12f 
 
5–17 
 
30–100g 
 
30–100g 
 
 10–20 
 
Pregabalin 
 
≥90 
 
0 1–2 
 
1–2 
 
5–7 
 
5–7 
 
 ?
h
 
 
Primidone 
 
≥90 
 
10 2–5 
 
2–4 
 
7–22 
 
3–12 
 
Metabolically 
derived 
phenobarbital 
contributes 
largely to 
clinical effects 
5–10i 
 
Tiagabine 
 
≥90 
 
96 0.5–2 
 
1–2 
 
5–9 
 
2–4 
 
 0.02–0.2 
 
Topiramate 
 
≥80 
 
15 2–4 
 
4–5 
 
20–30 
 
10–15 
 
 5–20 
 
Valproic acid 
 
≥90 
 
90
 j
 
 
3–6k 
 
2–4 
 
11–20 
 
6–12 
 
 50–100 
 
Vigabatrin 
 
≥60 
 
0 1–2 
 
1–2 
 
5–8 
 
5–8 
 
 0.8–36 
 
Zonisamide 
 
≥65 
 
50 2–5 
 
9–12 
 
50–70 
 
25–35 
 
 10–40 
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Table 2.1: Continued  
a
Immediate-release tablets; 
b
at the initiation of treatment, time to reach steady-state may be up to 5 weeks due to autoinduction. Reported 
half-lifes refer to patients on chronic therapy (half-lifes are considerably longer after a single dose); 
c
includes time to steady state for 
active metabolite N-desmethyl-clobazam; 
d
bioavailability decreases with increasing dosages; 
e
pharmacokinetic parameters, reference 
range and conversion factor refer to the active mono-hydroxy-derivative (MHD) metabolite;
 f
 bioavailability and rate of absorption 
depends on formulation; 
g
elimination is not first order, and half-life increases with increasing serum concentration; 
h
not established; 
i
phenobarbital concentrations should also be monitored; 
j
fraction bound to serum proteins decreases with increasing drug concentration; 
k
enteric-coated tablets ingested in a fasting state; 
l
these values are based on half-life values in the absence of interacting comedication. 
 
